Description
BRD1652 is a highly selective and potent GSK3 inhibitor. BRD1652 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3).
Uses
BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases[1].
in vivo
BRD1652 (30 mg/kg intraperitoneal injection, single dose) can reduce amphetamine-induced hyperactivity disorder (AIH) in mice[1].
References
[1] Wagner FF, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016 Jul 15;11(7):1952-63. DOI:
10.1021/acschembio.6b00306
